Cargando…

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

BACKGROUND: The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has shown clinical activity as monotherapy in phase I and II studies of advanced ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	LoRusso, Patricia M., Infante, Jeffrey R., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., Cohen, Roger B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340007/ https://www.ncbi.nlm.nih.gov/pubmed/28264648 http://dx.doi.org/10.1186/s12885-017-3143-6

Ejemplares similares

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
por: Rixe, Olivier, et al.
Publicado: (2015)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
por: Carvajal, Richard D., et al.
Publicado: (2015)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
por: Robert, Francisco, et al.
Publicado: (2009)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
por: Pant, Shubham, et al.
Publicado: (2013)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
por: Blegen, Kristina, et al.
Publicado: (2022)

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
por: Bendell, Johanna C, et al.
Publicado: (2015)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015)

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
por: Li, Tianhong, et al.
Publicado: (2016)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
por: Carducci, Michael A., et al.
Publicado: (2023)

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort
por: Burris, Howard A, et al.
Publicado: (2017)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors
por: Brendel, Erich, et al.
Publicado: (2010)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
por: Zheng, Xiaohang, et al.
Publicado: (2022)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors
por: Desar, Ingrid M. E., et al.
Publicado: (2012)

Dacarbazine-encapsulated solid lipid nanoparticles for skin cancer: physical characterization, stability, in-vivo activity, histopathology, and immunohistochemistry
por: Bhattacharya, Sankha, et al.
Publicado: (2023)

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
por: Lee, Choong-kun, et al.
Publicado: (2015)

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_ln1urj5g6qr19dungbq8v4ifpj